Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.3M
-
Number of holders
-
159
-
Total 13F shares, excl. options
-
61.1M
-
Shares change
-
+815K
-
Total reported value, excl. options
-
$2.18B
-
Value change
-
+$26.6M
-
Put/Call ratio
-
0.15
-
Number of buys
-
81
-
Number of sells
-
-66
-
Price
-
$35.79
Significant Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q1 2023
191 filings reported holding XENE - Xenon Pharmaceuticals Inc. - Common Stock as of Q1 2023.
Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 159 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 61.1M shares
of 77.3M outstanding shares and own 79.01% of the company stock.
Largest 10 shareholders include Avoro Capital Advisors LLC (4.9M shares), FMR LLC (4.73M shares), DRIEHAUS CAPITAL MANAGEMENT LLC (4.65M shares), Polar Capital Holdings Plc (3.02M shares), Capital International Investors (2.32M shares), MARSHALL WACE, LLP (2.32M shares), Capital World Investors (2.27M shares), BRAIDWELL LP (2.14M shares), PICTET ASSET MANAGEMENT SA (2M shares), and COMMODORE CAPITAL LP (1.85M shares).
This table shows the top 159 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.